CODEIS

Codexis has demonstrated that its proprietary enzyme engineering platforms can enable scalable, efficient, and greener manufacturing of small molecule APIs and siRNA therapeutics. Its ECO Synthesis™ platform has been validated by multiple CDMOs to reduce purification costs, improve process performance, and control stereochemistry in oligonucleotide synthesis. The company’s enzymes have enabled the manufacture of blockbuster drugs such as sitagliptin ("Januvia"), atorvastatin ("Lipitor"), and nirmatrelvir ("Paxlovid"). Recent presentations at TIDES USA highlighted reproducibility and process simplification for siRNA production. Codexis does not develop its own therapeutic pipeline but enables pharmaceutical companies to manufacture their products more efficiently.